COMMUNIQUÉS West-GlobeNewswire

Outlook Therapeutics Provides Update on Type A Meeting with FDA
29/09/2025
ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, [...]
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
29/09/2025
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics [...]
SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children
29/09/2025
Data show results consistent with clinical trial experience A high level of safety – no device-related adverse events Strong survival data extending to 90 days DENVER, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical [...]
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
29/09/2025
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- [...]
TOMI Environmental Solutions Strengthens Commercial Partnerships with Steri-Clean Adoption of SteraMist Technology
29/09/2025
Strategic Alliance with National Hoarding Cleanup Leader Advances TOMI's Franchise-Focused Growth Strategy and Addresses Rising Biohazard Challenges in the U.S. FREDERICK, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- TOMI [...]
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
29/09/2025
- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant - - Topline Results from ReSPECT Study Expected in 2Q [...]
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
29/09/2025
CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its [...]
Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India
29/09/2025
Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name of Vivos Scientific [...]
Sofwave to Participate in the Jefferies Virtual Private MedTech Summit
29/09/2025
SAN CLEMENTE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, [...]
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards
29/09/2025
New Taipei City, Taiwan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and [...]
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference
29/09/2025
Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were observed in patients [...]
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
29/09/2025
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar [...]
Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
29/09/2025
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; exploring additional [...]
Preeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corporate Name Change to Solana Company and Letter of Intent with Solana Foundation
29/09/2025
HSDT Solana Company's Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors HSDT enters into agreement [...]
Boehringer Ingelheim launches new direct-to-consumer platform to expand patient access to important treatments
29/09/2025
Ridgefield, Connecticut, U.S. Boehringer Ingelheim today announced the launch of its new direct-to-consumer platform , “Boehringer Ingelheim Access.” The platform will offer a convenient way for patients in the U.S. to [...]
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
29/09/2025
CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy [...]
Quotient Therapeutics Appoints Drug Discovery and Development Veteran, Andrew Bayliffe, as Chief Development Officer
29/09/2025
CAMBRIDGE, Mass., and CAMBRIDGE, United Kingdom, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has appointed [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
29/09/2025
KETAFREE™ to provide innovative, preservative-free IV ketamine formulation, eliminating toxic preservatives, in keeping with current HHS priorities to eliminate toxic preservatives from foods and drugs Filing is based [...]
Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation
29/09/2025
CHICAGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its Chief Executive [...]

Pages